Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Autologous Adipose Tissue Derived Mesenchymal Progenitor Cells Therapy for Patients With Knee Osteoarthritis by Intra-articular Injection: A Phase I, Prospective, Single-Arm, Dose-escalating Clinical Trial

Trial Profile

Autologous Adipose Tissue Derived Mesenchymal Progenitor Cells Therapy for Patients With Knee Osteoarthritis by Intra-articular Injection: A Phase I, Prospective, Single-Arm, Dose-escalating Clinical Trial

Completed
Phase of Trial: Phase I/II

Latest Information Update: 06 Apr 2016

At a glance

  • Drugs Mesenchymal stem cell therapy (Primary)
  • Indications Osteoarthritis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Cellular Biomedicine Group
  • Most Recent Events

    • 01 Apr 2016 According to ClinicalTrials.gov record number of treatment arms increased from 1 to 3, Secondary endpoint of Adverse Events made Primary and also time frame for this endpoint has been changed from 6 months to 3 months, Time frame for primary endpoint of WOMAC score has been changed from 6 months to 24 months.
    • 05 Dec 2014 Results presented at the 10th Annual World Stem Cell Summit (WSCS) and RegMed Capital Conference (RMCC), according to Cellular Biomedicine Group media release.
    • 05 Dec 2014 Results published in the Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top